Celltrion (CEO Woo-seong Ki) announced on the 31st that it will start a full-fledged support project to build a biocluster in Songdo, Incheon, as well as support all-around support to attract investment from global bio-health care companies.
Celltrion signed a business agreement with the global biopharmaceutical company Sartorius last month to invest 100 million dollars (about 108.5 billion won) in Songdo, Incheon to build a biopharmaceutical raw and subsidiary material manufacturing facility.
Global healthcare companies such as ThermoFisher Scientific, Avantor, and Cytiva are also accelerating investment discussions in various manufacturing and service supply facilities in Songdo, Incheon.
Thermofisher Scientific is a global healthcare company headquartered in Waltham, Massachusetts, USA. It supplies life science products and related technical services to the world, including Korea, and is reviewing investments in badge manufacturing facilities and distribution centers in Korea.
Headquartered in Pennsylvania, USA, Avanto is a global provider of products and services in the fields of life sciences, chemicals, and advanced materials. According to Celltrion, Avanto is considered to be considering investment in related production facilities in Korea.
Sitiba, which supplies major raw and subsidiary materials for Celltrion’s commercial medicines, is a global company that supplies products and services for biopharmaceutical research, development, and production. In 2016, the APAC Fast Trak Center was established and operated in Songdo, which is responsible for biopharmaceutical production process optimization services and process-related training. Since the recent spin-off from GE Healthcare, it has been working closely with Celltrion to establish additional investment plans in the Songdo area.
When these companies with global-level production and supply capabilities for major bio-raw materials make investments in various manufacturing facilities and distribution warehouses at the Songdo Bio Cluster in Incheon, Korean bio companies will more stably supply major raw materials and service services. It seems to be received.
In addition, it is expected to develop and supply core raw materials for biopharmaceuticals such as medium, and foster professional manpower through the development of customized training programs between supply and demand companies.
A celltrion official said, “As the demand for raw and subsidiary materials of bio companies around the world has exploded in the aftermath of the global Corona 19 pandemic, stable procurement of bio raw and subsidiary materials has become more important than ever.” He said, “We will actively support these companies and at the same time actively attract manufacturing facilities of overseas global companies to break away from the dependence on foreign countries for key raw and subsidiary materials and build a stable supply system.”
He added, “By attracting global companies to the Songdo biocluster, we will realize the reduction of the manufacturing cost of biopharmaceuticals, and will actively contribute to the development of the biohealthcare industry in Korea by growing Songdo into a global biocluster.”
[소비자가만드는신문=김경애 기자]
Copyright owner © Unauthorized reproduction and redistribution of newspapers made by consumers is prohibited.